



Dear Provider,

Your patient is interested in better understanding their personal risk for developing opioid use disorder (OUD). They would like you to consider ordering a genetic risk assessment for OUD called AvertD™.

AvertD (avertdtest.com) is a physician-ordered, laboratory developed test from SOLVD Health (solvdhealth.com) that analyzes 15 genetic markers involved in the brain reward pathways to identify if a patient is at high or low genetic risk for OUD. This clinically validated test requires only a simple cheek swab sample, which is mailed to our CLIA-certified, CAP-accredited lab for analysis. Results are made available to healthcare providers via a secure online portal.

AvertD is designed to be used prior to a first prescription for oral opioids to treat acute pain (pain lasting <30 days). When making prescribing decisions, AvertD offers an objective method of identifying which patients may be at increased genetic risk for developing OUD. This personalized risk information can help you and your patient make more informed decisions together when considering the use of prescription oral opioids.

In the published clinical validation study¹, AvertD demonstrated **82% sensitivity** and **80% specificity**. Patients with a high genetic risk were shown to be **16x more likely*** to develop OUD than patients with a low genetic risk.

Because genetics is only one of many known factors associated with increased risk for OUD, AvertD test results should be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in a pain management plan.

To learn more or get started, please give us a call at 1-760-598-1223, email us at info@solvdhealth.com, or visit <https://avertdtest.com/>. We are also happy to set up a call for you with our medical affairs team to answer any questions you may have.

We thank you for your consideration and would be honored to support you and your patients.

Best regards,

SOLVD Health Provider Relations
1-760-598-1223 | info@solvdhealth.com

¹Donaldson K, Cardamone D, Genovese M, Garbely J, Demers L. Clinical Performance of a Gene-Based Machine Learning Classifier in Assessing Risk of Developing OUD in Subjects Taking Oral Opioids: A Prospective Observational Study. Ann Clin Lab Sci July-August 2021 vol. 51 no. 4 451-460

*Based on an OUD prevalence of 5% in the post-surgical population

